Eoflow (294090) Q2 2025 earnings summary

Executive summary

• Specializes in wearable insulin pumps and related medical devices, with EOPatch as the flagship product, targeting the growing diabetes device market.

• Faced significant legal and financial challenges, including major ongoing litigation and a recent European sales ban on EOPatch due to patent infringement.

• Continued to invest in R&D, launching new products and expanding into artificial pancreas systems, but remains heavily loss-making.

Financial highlights

• 2025 H1 consolidated revenue: ₩1.90 billion, down from ₩3.13 billion in 2024 H1.

• Operating loss for 2025 H1: ₩(12.22) billion, compared to ₩(22.04) billion in 2024 H1.

• Net loss for 2025 H1: ₩(116.69) billion, a sharp increase from ₩(22.04) billion in 2024 H1, driven by extraordinary legal and financial expenses.

• Cash and equivalents at June 30, 2025: ₩2.38 billion, down from ₩3.39 billion at end-2024.

• Equity turned negative: ₩(94.72) billion at June 30, 2025, from ₩5.46 billion at end-2024.

Outlook and guidance

• Management highlights material uncertainty regarding going concern due to continued losses, liquidity pressure, and unresolved litigation.

• Plans to improve financial structure, negotiate with creditors, and pursue cost reductions and new funding.